论文部分内容阅读
目的 观察前列地尔脂微球载体制剂 (PGE1 )对肺心病心力衰竭患者的临床疗效及对肺动脉压力的影响。方法 将 4 0例肺心病患者随机分为两组 ,治疗组 2 5例 ,在心衰的常规治疗基础上加用 PGE1 2 0μg/天 ,共 14天 ;对照组 15例 ,为心衰常规治疗。观察治疗前后各组及组间心功能分级、心率、超声心动图及肺动脉压力的变化。结果 各组治疗后较治疗前相比心功能均有不同程度的改善 ,但治疗组更为明显 ,差异有显著性。同时治疗组肺动脉压力显著降低。结论 前列地尔脂微球载体制剂对肺心病心力衰竭患者有明显疗效 ,同时能显著降低肺动脉压力 ,使用方便安全
Objective To observe the clinical efficacy of alprostadil liposome microspheres preparation (PGE1) in patients with heart failure of pulmonary heart disease and its effect on pulmonary artery pressure. Methods 40 cases of patients with cor pulmonale were randomly divided into two groups, the treatment group 25 cases, in the conventional treatment of heart failure based on the use of PGE120μg / day for a total of 14 days; control group of 15 cases, the conventional treatment of heart failure . The changes of cardiac function, heart rate, echocardiography and pulmonary artery pressure before and after treatment were observed. Results Compared with before treatment, the cardiac function of all groups improved to some extent after treatment, but the treatment group was more obvious, the difference was significant. At the same time, pulmonary artery pressure in treatment group decreased significantly. Conclusions Alprostadil lipid microsphere carrier preparation has obvious curative effect on heart failure patients with cor pulmonale, meanwhile it can significantly reduce the pressure of pulmonary artery, and it is convenient and safe to use